Uterine leiomyosarcoma (U-LMS) is the most common histotype among all primary uterine sarcomas. The lung, peritoneum, pelvic or para-aortic lymph nodes, bone and liver are the most common metastatic sites involved. However, some case series of atypical sites of metastasis such as heart, brain and different endocrine glands have been described. Here we report the clinical presentation and therapeutic management of two patients affected by ULMS with a very atypical behavior, characterized by soft tissue metastases with an impressive and massive enlargement during chemotherapy despite a good control of the other sites of disease.

Development and Management of Massive Subcutaneous Metastases with Unusual Clinical Course from Uterine Leiomyosarcoma / DM, Filippini; G, Nuvola; M, Nannini; M, Saponara; S, Cammelli; Paolis M, De; AM, Perrone; Iaco P, De; Leo A, De; A, Astolfi; MA, Pantaleo. - In: JOURNAL OF CANCER SCIENCE AND CLINICAL THERAPEUTICS. - ISSN 2637-5079. - ELETTRONICO. - 05:04(2021), pp. 459-467. [10.26502/jcsct.5079131]

Development and Management of Massive Subcutaneous Metastases with Unusual Clinical Course from Uterine Leiomyosarcoma

DM, Filippini
Primo
;
G, Nuvola
;
M, Nannini;M, Saponara;S, Cammelli;AM, Perrone;Iaco P, De;A, Astolfi;MA, Pantaleo
Ultimo
2021

Abstract

Uterine leiomyosarcoma (U-LMS) is the most common histotype among all primary uterine sarcomas. The lung, peritoneum, pelvic or para-aortic lymph nodes, bone and liver are the most common metastatic sites involved. However, some case series of atypical sites of metastasis such as heart, brain and different endocrine glands have been described. Here we report the clinical presentation and therapeutic management of two patients affected by ULMS with a very atypical behavior, characterized by soft tissue metastases with an impressive and massive enlargement during chemotherapy despite a good control of the other sites of disease.
2021
Development and Management of Massive Subcutaneous Metastases with Unusual Clinical Course from Uterine Leiomyosarcoma / DM, Filippini; G, Nuvola; M, Nannini; M, Saponara; S, Cammelli; Paolis M, De; AM, Perrone; Iaco P, De; Leo A, De; A, Astolfi; MA, Pantaleo. - In: JOURNAL OF CANCER SCIENCE AND CLINICAL THERAPEUTICS. - ISSN 2637-5079. - ELETTRONICO. - 05:04(2021), pp. 459-467. [10.26502/jcsct.5079131]
DM, Filippini; G, Nuvola; M, Nannini; M, Saponara; S, Cammelli; Paolis M, De; AM, Perrone; Iaco P, De; Leo A, De; A, Astolfi; MA, Pantaleo
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/902562
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact